CA-ENCHROMA-INC
1.9.2022 20:05:34 CEST | Business Wire | Press release
EnChroma, Inc. – creators of glasses for color blindness – today announced the launch of International Color Blindness Awareness Month. During the entire month of September, EnChroma and over 50 museums, libraries, school districts, state and federal parks, universities, tourism agencies, and Lions and Kiwanis Clubs will make social media posts and publish other communications designed to educate their members, students, communities and/or followers about Color Vision Deficiency (CVD, or “color blindness”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005741/en/
Image courtesy of EnChroma @enchroma
“We are pleased that so many esteemed institutions have joined EnChroma to promote International Color Blindness Month to educate the world about the impact color vision deficiency has on people at work, in school, and in fully appreciating art or the colors of nature,” said Erik Ritchie, CEO of EnChroma. “More awareness will result in fewer daily frustrations for color blind people and more accessibility.”
Color blindness affects one in 12 men (8%) and one in 200 women (.5%); 350 million people worldwide. While people with normal color vision see over one million shades of color, those with Color Vision Deficiency only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red can appear brown. Click here for images depicting color blindness.
The 50+ organizations supporting International Color Blindness Month include:
• Georgia O'Keeffe Museum, NM |
• Boston University, MA |
• Faber-Castell, Germany |
• North Carolina State University, NC |
• Birmingham Museum of Art, AL |
• Anythink Libraries, CO |
• Museum of Contemporary Art Denver |
• Penn State University, Forensic Science Dept., PA |
|
• J.N. "Ding" Darling National Wildlife Refuge, FL |
• Fondazione Paolina Brugnatelli, Milan, Italy |
|
• Lions Club, District L, NC |
• Clinton-Macomb Public Library, MI |
• Cantigny Park, IL |
• Nelson-Atkins Museum of Art, MO |
• School District of New London, WI |
• Nahant Public Library, MA |
• Johnson County Public Library, IN |
• Dallas Museum of Art, TX |
• Lions Club, Adams, MN |
• RISD, Museum of Art, Rhode Island School of Design, RI |
• St. Johns County Public Libraries, FL |
|
• Alfred University, NY |
• Museum of Fine Arts, St. Petersburg, FL |
• i.d.e.a. Museum, AZ |
• Central High School (D301), IL |
• Kiwanis Club of Findlay, OH |
• Shelburne Museum, VT |
• Glen Ridge Public Library, NJ |
• Lions Club, District I, NC |
• Downers Grove Public Library, IL |
• National Museum of Wildlife Art, WY |
• Motlow State Community College, TN |
• Mulvane Art Museum, KS |
• Lions Club, District S, NC |
• Albrecht-Kemper Museum of Art, MO |
• Spiva Center for the Arts, MO |
• Eye See Color Project, FL |
• Helsingin Optiikka Oy, Finland |
• Plainfield Area Public Library, IN |
• Evansville Vanderburgh Public Library, IN |
•Technology Aids for the Blind & Visually Impaired, NC |
|
• Lions Club, District O, NC |
• Unique Optiek BV, The Netherlands |
• Lions Club, District N, NC |
• Carolyn Campagna Kleefeld Contemporary Art Museum, CA |
• Jonathan Jones Color Blind Fund, AZ |
|
EnChroma encourages other organizations and individuals to promote color blindness awareness anytime in September by posting to social media, websites and other forums using any of the templates located here, and/or images showing the color blind view of various settings here.
EnChroma Color Accessibility Program
EnChroma continues to lead in advocating for “color accessibility” through its EnChroma Color Accessibility Program, in which over 150 organizations participate. The program helps public venues such as schools, state parks, libraries, museums, tourism bureaus, resorts and other organizations loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the color blind.
Through the program, EnChroma donates a pair of glasses to an organization for every pair it purchases. Materials to educate teachers, parents, employers and others about color blindness, and how to support color blind students, children, employees and visitors, are also provided. EnChroma encourages schools to easily and quickly test all students for color blindness using its free online color vision test. Email accessibility@enchroma.com to learn about the program.
EnChroma’s patented lens technology helps people with red-green color blindness see an expanded range of colors and see them more vibrantly, clearly and distinctly. Studies by world-renowned color vision scientists at the University of California, Davis and France’s INSERM Stem Cell and Brain Research Institute, and the University of the Incarnate Word, have demonstrated the effectiveness of EnChroma glasses.
Story Assets for Media
Visit our Media Kit to download user videos, photos of EnChroma glasses and b-roll.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
